DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.<\/p>\n
Conferences Details:<\/p>\n
Event:<\/p>\n
LifeSci Genetics Medicine Conference<\/p>\n
Date:<\/p>\n
Tuesday, June 22, 2021<\/p>\n
Time:<\/p>\n
10:00 am ET<\/p>\n
Format:<\/p>\n
Fireside chat<\/p>\n
Participants:<\/p>\n
RA Session II, President, Founder and CEO<\/p>\n
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D<\/p>\n
Kamran Alam, Chief Financial Officer<\/p>\n<\/p>\n
Event:<\/p>\n
LSX Biotech Growth CEO Forum<\/p>\n
Topic:<\/p>\n
Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering<\/p>\n
Date:<\/p>\n
Tuesday, June 22, 2021<\/p>\n
Time:<\/p>\n
1:10 pm ET<\/p>\n
Format:<\/p>\n
Fireside chat<\/p>\n
Participants:<\/p>\n
RA Session II, President, Founder and CEO<\/p>\n
Webcasts for these conferences will be available in the Events & Media section of the Taysha corporate website at https:\/\/ir.tayshagtx.com\/news-events\/events-presentations<\/a>. Archived versions of the webcasts will be available on the website for 60 days.<\/p>\n About Taysha Gene Therapies <\/p>\n Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http:\/\/www.tayshagtx.com<\/a>.<\/p>\n<\/p>\n <\/p>\n More here: DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum. Conferences Details: Event: LifeSci Genetics Medicine Conference Date: Tuesday, June 22, 2021 Time: 10:00 am ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Continue reading
\nTaysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum - Business Wire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"